oral semaglutide for weight loss US FDA accepts Novo Nordisk's application Wegovy for FDA-Approved Oral Semaglutide Pills for

Piccinin E, Moschetta A

The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms. An estimated 1.6 million UK adults used GLP-1s such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) to lose weight between early 2024 and early 2025, with an additional 3.3 million interested in using weight loss drugs during 2026

They make it clear that these supplements are not a quick fix

Weight loss was also observed, with a modest correlation between alcohol reduction and weight change, suggesting GLP-1RAs may simultaneously target both alcohol use and obesity

Retrieved from Zhao, Z., Tang, Y., Hu, Y., et al

Li S, Lu S, Wang L, Liu S, Zhang L, Du J, et al